home / stock / lpcn / lpcn quote
Last: | $7.29 |
---|---|
Change Percent: | -0.51% |
Open: | $7.87 |
Close: | $7.29 |
High: | $7.9094 |
Low: | $7.105 |
Volume: | 30,288 |
Last Trade Date Time: | 07/05/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$7.29 | $7.87 | $7.29 | $7.9094 | $7.105 | 30,288 | 07-05-2024 |
$7.83 | $7.56 | $7.83 | $8.2266 | $7.502 | 21,743 | 07-04-2024 |
$7.83 | $7.56 | $7.83 | $8.2266 | $7.502 | 21,743 | 07-03-2024 |
$7.56 | $7.81 | $7.56 | $7.9 | $7.328 | 33,747 | 07-02-2024 |
$7.72 | $8.2 | $7.72 | $8.7081 | $7.63 | 22,325 | 07-01-2024 |
$8.24 | $7.68 | $8.24 | $8.27 | $7.1717 | 25,125 | 06-28-2024 |
$7.75 | $7.74 | $7.75 | $8.32 | $7.56 | 17,869 | 06-27-2024 |
$7.85 | $8.08 | $7.85 | $8.18 | $7.385 | 60,772 | 06-26-2024 |
$8.15 | $8.5 | $8.15 | $8.68 | $7.72 | 104,758 | 06-25-2024 |
$9.3 | $8.94 | $9.3 | $9.89 | $8.75 | 95,654 | 06-24-2024 |
$8.98 | $7.93 | $8.98 | $9.2 | $7.29 | 91,985 | 06-21-2024 |
$7.74 | $7.5 | $7.74 | $8.5394 | $7.35 | 160,268 | 06-20-2024 |
$7.18 | $11.01 | $7.18 | $11.79 | $6.27 | 446,337 | 06-19-2024 |
$7.18 | $11.01 | $7.18 | $11.79 | $6.27 | 446,337 | 06-18-2024 |
$10.69 | $9.55 | $10.69 | $10.85 | $9.3921 | 233,696 | 06-17-2024 |
$9.49 | $8.17 | $9.49 | $9.7399 | $8.14 | 164,659 | 06-14-2024 |
$8.18 | $7.97 | $8.18 | $8.1999 | $7.9 | 31,327 | 06-13-2024 |
$7.95 | $7.82 | $7.95 | $8.03 | $7.82 | 23,872 | 06-12-2024 |
$7.82 | $8 | $7.82 | $8.0135 | $7.53 | 61,862 | 06-11-2024 |
$7.98 | $7.88 | $7.98 | $8.25 | $7.46 | 84,037 | 06-10-2024 |
News, Short Squeeze, Breakout and More Instantly...
Lipocine Announces LPCN 1154 Meets Bioequivalence with IV Brexanolone in Pivotal Study PR Newswire Met standard bioequivalence (BE) criteria C max, AUC 0-t , and AUC 0- ∞ C trough criterion was met LPCN 1154 was well tolerat...
Shares of Lipocine Inc. (NASDAQ: LPCN) traded at a new 52-week high today and are currently trading at $8.96. So far today, approximately 78,318 shares have been exchanged, as compared to an average 30-day volume of 32,701 shares. Lipocine Inc., a clinical-stage biopharmaceutical company, foc...
Lipocine Presents 52 Week Results from LPCN 1148 Phase 2 Study in Late Breaking Session at EASL Congress 2024 PR Newswire SALT LAKE CITY , June 10, 2024 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company, today announced that Phase 2 r...